Immunotherapy is now recognized as an essential component of treatment for a wide variety of cancers. It is an interdisciplinary field that is critically dependent upon an improved understanding of a vast network of cross-regulatory cellular populations and a diversity of molecular effectors; it is a leading example of translational medicine with a favorable concept-to-clinical-trial timeframe of just a few years. There are many established immunotherapies already in existence, but there are exciting new cancer immunotherapies just on the horizon, which are likely to be more potent, less toxic and more cost effective than many therapies currently in use. Experimental and Applied Immunotherapy is a state-of-the-art text offering a roadmap leading to the creation of these future cancer-fighting immunotherapies. It includes essays by leading researchers that cover a wide variety of topics including T cell and non-T cell therapy, monoclonal antibody therapy, dendritic cell-based cancer vaccines, mesenchymal stromal cells, negative regulators in cancer immunology and immunotherapy, non-cellular aspects of cancer immunotherapy, the combining of cancer vaccines with conventional therapies, the combining of oncolytic viruses with cancer immunotherapy, transplantation, and more. The field of immunotherapy holds great promise that will soon come to fruition if creative investigators can bridge seemingly disparate disciplines, such as T cell therapy, gene therapy, and transplantation therapy. This text is a vital tool in the building of that bridge.
Author(s): Ulrike Gerdemann, Malcolm K. Brenner (auth.), Jeffrey Medin, Daniel Fowler (eds.)
Edition: 1
Publisher: Humana Press
Year: 2011
Language: English
Pages: 442
Tags: Immunology; Cell Biology
Front Matter....Pages i-xvii
Front Matter....Pages 1-1
Extending the Use of Adoptive T Cell Immunotherapy for Infections and Cancer....Pages 3-33
Front Matter....Pages 35-35
B Lymphocytes in Cancer Immunology....Pages 37-57
Monoclonal Antibody Therapy for Cancer....Pages 59-83
Natural Killer Cells for Cancer Immunotherapy....Pages 85-105
Dendritic Cell-Based Cancer Vaccines: Practical Considerations....Pages 107-126
Mesenchymal Stromal Cells: An Emerging Cell-Based Pharmaceutical....Pages 127-148
Front Matter....Pages 149-149
Tumor-Specific Mutations as Targets for Cancer Immunotherapy....Pages 151-172
Counteracting Subversion of MHC Class II Antigen Presentation by Tumors....Pages 173-194
Mechanisms and Implications of Immunodominance in CD8 + T-Cell Responses....Pages 195-206
T Regulatory Cells and Cancer Immunotherapy....Pages 207-228
Negative Regulators in Cancer Immunology and Immunotherapy....Pages 229-249
Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy....Pages 251-278
Front Matter....Pages 279-279
Cytokine Immunotherapy....Pages 281-305
Transcriptional Modulation Using Histone Deacetylase Inhibitors for Cancer Immunotherapy....Pages 307-322
Combining Cancer Vaccines with Conventional Therapies....Pages 323-338
Combining Oncolytic Viruses with Cancer Immunotherapy....Pages 339-355
Radiation Therapy and Cancer Treatment: From the Basics to Combination Therapies that Ignite Immunity....Pages 357-388
Assessing Immunotherapy Through Cellular and Molecular Imaging....Pages 389-408
Front Matter....Pages 409-409
Allogeneic and Autologous Transplantation Therapy of Cancer: Converging Themes....Pages 411-430
Back Matter....Pages 431-442
